Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain
- 15 October 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 19 (1) , 25-35
Abstract
Neuropathic pain and chronic inflammatory pain are large unmet medical needs. Over the past two decades, numerous 'pain targets' have been identified for analgesic drug discovery. Despite promising results in rodent pain models, many compounds modulating such targets lacked efficacy in clinical trials. An exception is oral EMA401, a small-molecule angiotensin II type 2 receptor (AT2R) antagonist. Herein, angiotensin II/AT2R signaling-induced hyperexcitability and abnormal sprouting of cultured dorsal root ganglion neurons, together with radioligand binding, pharmacokinetics, analgesic efficacy and mode of action of small-molecule AT2R antagonists in rodent models of peripheral neuropathic and chronic inflammatory pain, are reviewed. The findings of a successful Phase IIa clinical trial of EMA401 in patients with neuropathic pain are presented in brief. The functional importance of angiotensin II/AT2R signaling has remained enigmatic for decades, and there are no clinically available medications that target the AT2R. However, on the basis of preclinical findings and recent clinical trial data showing that the peripherally restricted, small-molecule AT2R antagonist, EMA401, successfully alleviated neuropathic pain in a Phase II clinical trial, the AT2R is receiving considerable attention as a new therapeutic target with human validation for the relief of peripheral neuropathic and chronic inflammatory pain conditions.Keywords
This publication has 47 references indexed in Scilit:
- EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trialThe Lancet, 2014
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathyScandinavian Journal of Pain, 2013
- Current challenges in translational pain researchTrends in Pharmacological Sciences, 2012
- An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the kneePain, 2012
- Overcoming obstacles to developing new analgesicsNature Medicine, 2010
- The evidence for pharmacological treatment of neuropathic painPain, 2010
- Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature UpdateMayo Clinic Proceedings, 2010
- Pain Management: A Fundamental Human RightAnesthesia & Analgesia, 2007
- Dose-Response Study of the Analgesic Effect of Lanepitant in Patients with Painful Diabetic NeuropathyClinical Neuropharmacology, 2001